IASLC Lung Cancer Staging Project Understanding the Complexities

IASLC Lung Cancer Staging Project Understanding the Complexities

thoraciconcology

1 year
187 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Jessica S. Donington, MD of NYU Langone Health discusses IASLC lung cancer staging project, important changes and complexities. There are big changes involved, including further delineation of the T-stage by tumor size with cut-offs at 1, 2, 3, 4, 5 and 7 cm. More tumor size does matter in terms of the prognosis, and fortunately, the end stage didnt change at all. However, there are three additional M-stages: M1a (Interthoracic Metastatic Spread); M1b (Oligo Metastatic Spread) and M1c (Multiple Sites). Dr. Donington believes that some of these changes will translate into different treatment options. As for the complexities in the staging, there are more subsets and smaller differentiation between stages to better predict prognosis. However, in this way, doctors can treat smaller stage subgroup in a more refined manner and they can give more accurate prognosis.
Up Next Autoplay
POSEIDON Reaps Success for Imfinzi in Non-Small Cell Lung Cancer from AstraZeneca, GlobalData says
POSEIDON Reaps Success for Imfinzi in Non-Small Cell Lung Cancer from AstraZeneca, GlobalData says
Category: Non-Small Cell Lung Cancer
0 Views
Cancer-News 7 minutes
Anti–PD-1/PD-L1 Antibody Immunotherapy Commonly Asked Questions @CleClinicMD
Anti–PD-1/PD-L1 Antibody Immunotherapy Commonly Asked Questions @CleClinicMD
Category: Immunotherapy
0 Views
Cleveland Clinic 24 minutes
Response to Anti–PD-1/PD-L1  Antibody Immunotherapy @CleClinicMD
Response to Anti–PD-1/PD-L1 Antibody Immunotherapy @CleClinicMD
Category: Immunotherapy
1 Views
Cleveland Clinic 38 minutes
ONC201 and ONC206 Activity in Neuro-Oncology to be Presented at SNO Conference
ONC201 and ONC206 Activity in Neuro-Oncology to be Presented at SNO Conference
Category: News
2 Views
alexvarney 1 hour
Investigational Melanoma Vaccine, Seviprotimut-L: Moving Forward
Investigational Melanoma Vaccine, Seviprotimut-L: Moving Forward
Category: Melanoma and Skin Cancer
2 Views
UVA Cancer Center 15 hours
Publication in Nature Communications Confirms DRD2 as Target of ONC201
Publication in Nature Communications Confirms DRD2 as Target of ONC201
Category: News
3 Views
alexvarney 21 hours
Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma Published
Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma Published
Category: Brain Cancer
2 Views
alexvarney 22 hours
An Advocates Perspective to Increasing Funding Resources
An Advocates Perspective to Increasing Funding Resources
Category: Kidney Cancer
39 Views
kidneycancer 1 day
Phase III Data for Investigational Melanoma Vaccine, Seviprotimut-L #SITC @UVACancerCenter
Phase III Data for Investigational Melanoma Vaccine, Seviprotimut-L #SITC @UVACancerCenter
Category: Melanoma and Skin Cancer
11 Views
UVA Cancer Center 1 day
Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits
Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits
Category: News
3 Views
Cancer-News 2 days